Updated Jul 16, 2026
Freeman Chris has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.90M.
Chris Freeman is the Chief Commercial Officer at Guardant Health, Inc., a company specializing in liquid-based cancer tests. He has been involved in the company's commercial strategies and operations, contributing to its growth in the oncology diagnostics market.
| Role | Chief Commercial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 3.1K | $170.77 | $536K |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 1.3K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 2.5K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 1.7K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 1.9K | $0.00 | |
| 2026-06-16 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 594 | $129.82 | $77K |
| 2026-06-16 | GH | Guardant Health, Inc. | M — Option exercise | 1.4K | $0.00 | |
| 2026-05-26 | GH | Guardant Health, Inc. | S — Open-market sale | 24.4K | $118.67 | $2.90M |
| 2026-05-26 | GH | Guardant Health, Inc. | M — Option exercise | 24.4K | $32.86 | $802K |
| 2026-04-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 4.8K | $91.15 | $433K |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 5.1K | $0.00 | |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 2.5K | $0.00 | |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 1.7K | $0.00 | |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 1.9K | $0.00 | |
| 2026-03-17 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 7.1K | $85.49 | $609K |
| 2026-03-17 | GH | Guardant Health, Inc. | M — Option exercise | 1.4K | $0.00 | |
| 2026-03-17 | GH | Guardant Health, Inc. | M — Option exercise | 15.4K | $0.00 | |
| 2025-10-01 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 5.7K | $62.65 | $360K |
| 2025-10-01 | GH | Guardant Health, Inc. | M — Option exercise | 10.0K | $0.00 | |
| 2025-10-01 | GH | Guardant Health, Inc. | M — Option exercise | 1.7K | $0.00 |
Chris Freeman is the Chief Commercial Officer at Guardant Health, Inc., a company specializing in liquid-based cancer tests. He has been involved in the company's commercial strategies and operations, contributing to its growth in the oncology diagnostics market.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($2.90M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Freeman Chris profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.